American Association for Cancer Research
21598290cd160164-sup-161869_2_supp_0_l8tk75.pdf (213.69 kB)

Supplementary Methods from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer

Download (213.69 kB)
journal contribution
posted on 2023-04-03, 21:06 authored by Haikuo Zhang, Jun Qi, Jaime M. Reyes, Lewyn Li, Prakash K. Rao, Fugen Li, Charles Y. Lin, Jennifer A. Perry, Matthew A. Lawlor, Alexander Federation, Thomas De Raedt, Yvonne Y. Li, Yan Liu, Melissa A. Duarte, Yanxi Zhang, Grit S. Herter-Sprie, Eiki Kikuchi, Julian Carretero, Charles M. Perou, Jacob B. Reibel, Joshiawa Paulk, Roderick T. Bronson, Hideo Watanabe, Christine Fillmore Brainson, Carla F. Kim, Peter S. Hammerman, Myles Brown, Karen Cichowski, Henry Long, James E. Bradner, Kwok-Kin Wong

Supplementary Methods


Deutsche Forschungsgemeinschaft



the Gross-Loh Family Fund for Lung Cancer Research and Susan Spooner Family Lung Cancer Research Fund at Dana-Farber Cancer Institute.

Burroughs Wellcome Fund

William Lawrence and Blanche Hughes Foundation

Leukemia and Lymphoma Society



As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non–small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression. To target EZH2-dependent cancers, we developed a potent open-source EZH2 inhibitor, JQEZ5, that promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a subset of lung cancer.Significance: EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity. Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer. Cancer Discov; 6(9); 1006–21. ©2016 AACR.See related commentary by Frankel et al., p. 949.This article is highlighted in the In This Issue feature, p. 932